Bowel cancer “melted away” after immunotherapy, then stayed away
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had…
The NEOPRISM-CRC clinical trial, led by researchers at UCL and UCLH, has shown promising results in treating a specific form of bowel cancer. Patients who received a short course of immunotherapy, pembrolizumab, prior to surgery experienced a significant reduction in tumor size and remained cancer-free for nearly three years after the treatment.
This outcome is substantially better than the typical 25% relapse rate among patients who undergo standard surgery followed by chemotherapy. The study's findings suggest that this pre-surgery immunotherapy approach may offer more durable cancer control compared to traditional treatment methods. Additionally, researchers developed personalized blood tests to monitor treatment efficacy and predict patient response, potentially enabling more targeted and personalized cancer care.
Brief written by urgent.news from ScienceDaily's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Bowel cancer “melted away” after immunotherapy, then stayed away sciencedaily.com
